Although previous studies have suggested the interest of targeting Sec61 in Oncology, therapeutic indications and in vivo safety of Sec61 blockers as anti‐cancer agents have remained unexplored (Luesch & Paavilainen, 2020). This evidence concerns the gene SEC61A1 and cancer.